- Home
- MGRX vs PMCB Comparison
MGRX vs PMCB Comparison
Compare MGRX & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- PMCB
- Stock Information
- Founded
- MGRX 2021
- PMCB 1996
- Country
- MGRX United States
- PMCB United States
- Employees
- MGRX N/A
- PMCB N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGRX Technology
- PMCB Health Care
- Exchange
- MGRX Nasdaq
- PMCB Nasdaq
- Market Cap
- MGRX 8.1M
- PMCB 7.1M
- IPO Year
- MGRX 2023
- PMCB N/A
- Fundamental
- Price
- MGRX $2.04
- PMCB $1.02
- Analyst Decision
- MGRX
- PMCB
- Analyst Count
- MGRX 0
- PMCB 0
- Target Price
- MGRX N/A
- PMCB N/A
- AVG Volume (30 Days)
- MGRX 204.7K
- PMCB 9.9K
- Earning Date
- MGRX 05-15-2025
- PMCB 03-17-2025
- Dividend Yield
- MGRX N/A
- PMCB N/A
- EPS Growth
- MGRX N/A
- PMCB N/A
- EPS
- MGRX N/A
- PMCB 1.29
- Revenue
- MGRX $511,084.00
- PMCB N/A
- Revenue This Year
- MGRX N/A
- PMCB N/A
- Revenue Next Year
- MGRX N/A
- PMCB N/A
- P/E Ratio
- MGRX N/A
- PMCB $0.79
- Revenue Growth
- MGRX N/A
- PMCB N/A
- 52 Week Low
- MGRX $1.32
- PMCB $1.00
- 52 Week High
- MGRX $7.66
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- MGRX 52.44
- PMCB 41.38
- Support Level
- MGRX $2.05
- PMCB $1.05
- Resistance Level
- MGRX $2.28
- PMCB $1.14
- Average True Range (ATR)
- MGRX 0.24
- PMCB 0.07
- MACD
- MGRX 0.06
- PMCB 0.01
- Stochastic Oscillator
- MGRX 57.56
- PMCB 13.33
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.